First-ever WHO Immunization Recommendations for Infant RSV
The World Health Organization issued its first-ever recommendations for immunizing infants against RSV, which is the leading cause of acute lower respiratory infections in children globally.
Category: RSV
RSV
Latest
First-ever WHO Immunization Recommendations for Infant RSV
The World Health Organization issued its first-ever recommendations for immunizing infants against RSV, which is the leading cause of acute lower respiratory infections in children globally.
Read More
CDC: ‘The Decision to Vaccinate Is a Personal One’
A recent CDC statement may signal a shift in the agency’s longstanding practice of advocating vaccinations for infectious diseases like measles.
Read More
New Approach for Antiviral Development
A new antiviral modeling approach combines various experimental techniques to create a comprehensive picture of a virus’ dynamic behavior.
Read More
RSV Vaccine Program for Seniors Cut Hospitalizations by 62%
An RSV vaccine program targeted at seniors in Scotland found 68% of adults aged 75-79 were vaccinated which led to a 62% reduction in RSV-related hospitalizations.
Read More
FDA Mandates Guillain-Barré Syndrome Warning for Two RSV Vaccines
The FDA has required Guillain-Barré syndrome warnings to be added to prescribing information for RSV vaccines Abrysvo and Arexvy.
Read More
American Confidence in RSV Vaccines Rises, Survey Finds
A new Annenberg Public Policy Center survey reveals evolving public attitudes toward vaccines—including RSV, flu, COVID-19, and MMR—in the United States.
Read More
RSV Vaccine Effectiveness Lower in Immunocompromised Older Adults
Johns Hopkins Medicine says further research is needed to better understand the problem and find ways to enhance immune response in this high-risk population.
Read More
Best Window for RSV Vaccination During Pregnancy Identified
Current guidelines recommend RSV vaccination between 32-36 weeks of pregnancy, but researchers have identified the optimal time within that window for maximum newborn protection.
Read More
Pfizer’s RSV Vaccine Approved for Adults Down to Age 18
The FDA has approved Pfizer’s RSV vaccine, Abrysvo, for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease caused by RSV, expanding its previous indication for adults aged 60 and older.
Read More
RSV Is Linked to Asthma in Children – But We Can’t Say One Causes the Other Yet
While respiratory syncytial virus, or RSV, is strongly associated with asthma in children, the exact relationship remains unclear.
Read More
Pfizer’s RSV Vaccine Shows Promise in Immunocompromised Adults
Pfizer’s Abrysvo demonstrated a strong immune response and favorable safety profile in immunocompromised adults at high risk of severe RSV.
Read More
Under 75? CDC Revises RSV Vaccine Recommendations for High-Risk Only
The CDC’s updated guidance recommends vaccination only for high-risk adults aged 60-74, while strengthening its advice for adults 75 and older.
Read More
FDA Expands Approval of Arexvy for Adults Age 50-59
GlaxoSmithKline’s RSV vaccine Arexvy is now available for at-risk adults age 50-59 in addition to those age 60 and older.
Read More
FDA Approves Moderna RSV Vaccine
mRESVIA is the first mRNA vaccine approved for a disease other than COVID-19 and is the only RSV vaccine available in single-dose pre-filled syringes.
Read More
Tool Identifies Newborns at Highest Risk for Severe RSV
Researchers have created a new tool to identify newborns at the highest risk for severe RSV, enhancing the prioritization of immunoprophylaxis during shortages.
Read More
WHO Overturns Dogma on Airborne Disease Spread. The CDC Might Not Act on It.
The World Health Organization has issued a report that transforms how the world understands respiratory infections like COVID-19, influenza, and measles.
Read More
WHO Updates Terminology for Airborne Pathogens
The report introduces the term “infectious respiratory particles” and advocates for moving away from the dichotomy of the previously used terms “aerosols” and “droplets.”
Read More
PAHO Report on Respiratory Virus Circulation
News Brief: Pan American Health Organization The Pan American Health Organization (PAHO) this week...
Read More
The Overlooked Phenomenon of ‘Long Colds’
Scientists suggest that extended ailments, termed “long colds,” can also arise from non-COVID respiratory infections.
Read More
Decongestant in Popular OTC Cold and Allergy Meds Doesn’t Work, FDA Panel Says
An FDA advisory committee determined that phenylephrine, common in brands like Benadryl and Mucinex, is ineffective as a nasal decongestant.
Read More
Most Infants Receiving ICU-level Care for RSV Were Previously Healthy
A CDC-supported study found the majority of infants admitted to the intensive care or high acuity unit for RSV during fall 2022 were previously healthy and born at term.
Read More
Pediatric Asthma Diagnoses Declined 52% During Pandemic
Half as many children in the United States were diagnosed with asthma in the first year of the COVID-19 pandemic compared to previous years, perhaps due to a fewer number of common colds, according to Rutgers University researchers.
Read More
Sulforaphane in Broccoli Slowed COVID, Common Cold
Sulforaphane, a plant-derived chemical found in broccoli and other leafy vegetables, can inhibit the replication of COVID and another human coronaviruses in cells and mice.
Read More
Rhinovirus, Enterovirus Continued to Circulate During Pandemic
While flu, RSV, and other respiratory virus infections declined sharply, rhinovirus/enterovirus persisted and continued to circulate among children.
Read More